FDAnews
www.fdanews.com/articles/209480-aleva-neurotherapeutics-gets-ce-approval-of-mri-label-for-directstim-dbs-system

Aleva Neurotherapeutics Gets CE Approval of MRI Label for DirectSTIM DBS System

September 21, 2022

Aleva Neurotherapeutics has earned a CE mark for its DirectSTIM deep brain stimulation system for use with full-body magnetic resonance imaging (MRI) equipment.

The system is designed to treat the symptoms of Parkinson’s disease by delivering precisely targeted electrical stimulation in the brain to provide symptom relief and better control of side effects, the company said.

The new MRI labeling allows the use of the system for patients who undergo an MRI exam after deep brain stimulation surgery.

The Switzerland-based company is focused on improving existing deep brain stimulation treatments for patients with neurological disorders.

View today's stories